01:24 PM EDT, 10/10/2024 (MT Newswires) -- Pfizer ( PFE ) and BioNTech's (BNTX) adapted Covid-19 vaccine Comirnaty that targets the KP.2 subvariant was approved for adults in the UK, the Medicines and Healthcare Products Regulatory Agency said Thursday.

The regulator said the adapted vaccine met its safety, quality, and effectiveness standards.

The agency also said it approved two presentations of the Comirnaty KP.2 30 micrograms per dose dispersion for injection, in multidose vials and in pre-filled syringe.

Shares of Pfizer ( PFE ) were down 2.6%, while BioNTech shares were marginally advancing in recent trading.

Price: 29.41, Change: -0.79, Percent Change: -2.60